Septerna (NASDAQ:SEPN) Reaches New 12-Month High – Here’s Why

Septerna, Inc. (NASDAQ:SEPN)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as $40.65 and last traded at $38.2550, with a volume of 303743 shares. The stock had previously closed at $38.83.

Analyst Ratings Changes

A number of research firms have recently commented on SEPN. Guggenheim cut their target price on Septerna from $52.00 to $45.00 and set a “buy” rating on the stock in a research note on Wednesday, July 1st. Stifel Nicolaus assumed coverage on Septerna in a research report on Friday, May 1st. They issued a “buy” rating and a $43.00 price target for the company. Raymond James Financial upped their price target on shares of Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research note on Monday, June 8th. Truist Financial increased their price objective on shares of Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $45.89.

Septerna Trading Down 2.5%

The company has a market capitalization of $1.74 billion, a PE ratio of -47.78 and a beta of 2.29. The business’s fifty day moving average is $34.40 and its two-hundred day moving average is $29.02.

Septerna (NASDAQ:SEPN) last issued its earnings results on Monday, May 11th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. The business had revenue of $26.52 million for the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. As a group, equities research analysts anticipate that Septerna, Inc. will post -1.59 EPS for the current year.

Insiders Place Their Bets

In related news, SVP Daniel D. Long sold 15,000 shares of Septerna stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $35.51, for a total value of $532,650.00. Following the completion of the sale, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,423,590.12. This trade represents a 13.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samira Shaikhly sold 11,798 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the transaction, the insider directly owned 793 shares of the company’s stock, valued at approximately $23,837.58. This trade represents a 93.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 47,828 shares of company stock worth $1,584,314. Corporate insiders own 5.80% of the company’s stock.

Institutional Trading of Septerna

A number of institutional investors have recently made changes to their positions in SEPN. TRV GP V LLC bought a new stake in shares of Septerna in the second quarter worth approximately $208,160,143,000. TRV GP VI LLC purchased a new position in shares of Septerna during the second quarter valued at approximately $141,048,460,000. BlackRock Inc. bought a new position in Septerna during the second quarter valued at approximately $64,706,000. Deutsche Bank AG bought a new position in Septerna during the second quarter valued at approximately $733,000. Finally, Bank of New York Mellon Corp purchased a new stake in Septerna in the second quarter worth approximately $1,881,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.